Hope for Friedreich's ataxia: new drug trial aims to slow disease progression

NCT ID NCT06447025

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing the long-term safety and effectiveness of an experimental drug called CTI-1601 for people with Friedreich's ataxia, a rare genetic disease that affects movement and heart function. It includes about 85 adolescents and adults who have or have not taken the drug before. Participants receive daily injections, and researchers will monitor side effects, heart health, motor skills, and daily living abilities over time.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FRIEDREICH ATAXIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Children's Hospital of the University of Pennsylvania (CHOP)

    RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

  • Clinilabs Drug Development, Corp.

    RECRUITING

    Eatontown, New Jersey, 07724, United States

  • Fixel Institute for Neurological Disease, University of Florida Health

    ACTIVE_NOT_RECRUITING

    Gainesville, Florida, 32608, United States

  • Morsani Center for Advanced Health Care, University of South Florida Health

    RECRUITING

    Tampa, Florida, 33612, United States

  • Ohio State University United States

    ACTIVE_NOT_RECRUITING

    Columbus, Ohio, 43210, United States

  • Uncommon Cures

    RECRUITING

    Chevy Chase, Maryland, 20815, United States

  • University of California Los Angeles

    RECRUITING

    Los Angeles, California, 90095, United States

  • University of Iowa

    RECRUITING

    Iowa City, Iowa, 52242, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.